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Vitamin c alleviates acute 
enterocolitis in Campylobacter 
jejuni infected mice
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Human foodborne infections with the zoonotic pathogen Campylobacter jejuni are on the rise and 
constitute a significant socioeconomic burden worldwide. The health-beneficial, particularly anti-
inflammatory effects of vitamin C (ascorbate) are well known. In our preclinical intervention study, we 
assessed potential anti-pathogenic and immunomodulatory effects of ascorbate in C. jejuni-infected 
secondary abiotic IL-10−/− mice developing acute campylobacteriosis similar to humans. Starting 4 
days prior peroral C. jejuni-infection, mice received synthetic ascorbate via the drinking water until the 
end of the experiment. At day 6 post-infection, ascorbate-treated mice harbored slightly lower colonic 
pathogen loads and suffered from less severe C. jejuni-induced enterocolitis as compared to placebo 
control animals. Ascorbate treatment did not only alleviate macroscopic sequelae of infection, but also 
dampened apoptotic and inflammatory immune cell responses in the intestines that were accompanied 
by less pronounced pro-inflammatory cytokine secretion. Remarkably, the anti-inflammatory 
effects of ascorbate pretreatment in C. jejuni-infected mice were not restricted to the intestinal tract 
but could also be observed in extra-intestinal compartments including liver, kidneys and lungs. In 
conclusion, due to the potent anti-inflammatory effects observed in the clinical murine C. jejuni-
infection model, ascorbate constitutes a promising novel option for prophylaxis and treatment of acute 
campylobacteriosis.
Campylobacter jejuni are the most common cause of food-borne gastroenteritis with increasing prevalence world-
wide1,2. In fact, human campylobacteriosis represents a socioeconomic burden given estimated disease-associated 
costs of approximately 2.4 billion Euro3. Most commonly, C. jejuni transfer via consumption of contaminated 
raw or undercooked meat and milk or the ingestion of contaminated surface water to humans4–8. The intestinal 
colonization of C. jejuni induces a strong inflammatory response of the innate immune system affecting both, 
absorptive and secretory functions of the gastrointestinal tract1. In fact, campylobacteriosis constitutes a classical 
sodium malabsorption syndrome9, which depending on the bacterial strain and the host immune status, results 
in illness of varying degree10. Whereas some patients remain asymptomatic or display mild symptoms, others 
develop fever, abdominal pain and watery diarrhea, or suffer from acute campylobacteriosis characterized by 
severe enterocolitis with inflammatory, bloody diarrhea1,11. In the majority of events, the disease is self-limited 
and treated symptomatically, whereas patients with immunosuppressive comorbidities require antibiotic 
treatment11,12. However, in few instances, post-infectious sequelae including Guillain-Barré syndrome, Miller 
Fisher syndrome, reactive arthritis and chronic inflammatory conditions of the intestinal tract might develop 
with a latent period of weeks or longer1,13.
Even though human campylobacteriosis is becoming increasingly important, the distinct cellular and molecu-
lar mechanisms of host-pathogen interactions are limited. Clinical investigations in human patients disclosed that 
severe courses of Campylobacter infection and post-infectious morbidities (e.g., Guillain-Barré syndrome) are 
induced by the Gram-negative bacterial cell wall constituent lipooligosaccharide (LOS), especially sialylated LOS, 
which leads to hyper-activating of immune response14. Further RNA sequencing studies in human volunteers 
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confirmed the major role of LOS-induced toll-like receptor (TLR) -4 signaling pathways in the induction of acute 
campylobacteriosis9. These findings support the view that campylobacteriosis results from a LOS-induced, TLR-4 
mediated hyperergic innate immune response, which is similar to the inflammatory events induced by other 
LOS producing pathogens like Neisseria meningitidis and N. gonorrhoeae. However, in vivo trials have been ham-
pered by the limited availability of experimental models. Mice show a strong physiological colonization resist-
ance against invading microorganisms due to the mouse specific gut microbiota composition and are therefore 
protected from infection with enteropathogenic bacteria such as C. jejuni15–17. Furthermore, when compared 
to human, mice have been shown to be about 10,000-fold more resistant against LOS and lipopolysaccharide 
(LPS) expressed by Gram-negative bacteria18–20. We could recently show that a depletion of the gastrointesti-
nal microbiota upon broad-spectrum antibiotic application in IL-10−/− mice facilitates intestinal C. jejuni col-
onization resulting in the development of key symptoms of acute human campylobacteriosis including wasting 
and bloody diarrhea within several days post-infection21. The main reasons for these severe C. jejuni induced 
immunopathological responses mounting in acute ulcerative enterocolitis are (i.) the abrogation of colonization 
resistance following microbiota depletion and (ii.) the lack of IL-10 enhancing susceptibility of mice to C. jejuni 
LOS21. In consequence, secondary abiotic IL-10−/− mice challenged with C. jejuni show strong intestinal and 
extra-intestinal immune responses via LOS–induced TLR-4 signaling21–30. Most importantly, the major role of 
LOS-induced intestinal immunopathology during campylobacteriosis was independently confirmed in elegant 
infection experiments with microbiota depleted SIGGR−/− mice developing campylobacteriosis similar to sec-
ondary abiotic IL-10 deficient mice. In contrast to the latter, the SIGGR−/− mice rendered sensitive to LOS due to 
the lack of a central inhibitor of cellular LPS/LOS-induced signaling pathways31.
In the 1920s, vitamin C was first isolated by the Hungarian Nobel laureate Albert Szent Györgyi on track 
to unravel the options for treatment and prophylaxis of morbidities such as scurvy caused by deficiency of this 
(for humans essential) vitamin32,33. Patients suffering from scurvy exhibit poor wound healing due to weaken-
ing of collagenous structures and compromised immune cell functions34 and are therefore highly susceptible to 
infections32,35. Ascorbate, the biologically active form of vitamin C, exerts a strong reductive potential and acts 
as a potent antioxidant that can be reversibly oxidized to dehydroascorbic acid33,36. Due to these characteristics, 
ascorbate is involved in several pivotal host defenses including immune regulatory pathways35. This is further 
underlined by the fact that both, innate and adaptive immune cells such as neutrophils, monocytes and lym-
phocytes, respectively, can accumulate ascorbate against a concentration gradient and exhibit intracellular con-
centrations that are up to 100 times higher than in plasma36–38. The presence of ascorbate in cells and plasma 
protects from oxidative stress. It is known that during phagocytosis, human granulocytes release hydrogen per-
oxide (H2O2) into the extracellular medium subsequently causing oxidative stress39 and cell damage by lipid 
peroxidation and alteration of protein and nucleic acid structure40. Interestingly, due to this potent antioxidant 
property, ascorbate has been shown to neutralize H2O2 and to reduce the H2O2-induced apoptosis in periodontal 
tissues41. Moreover, endotoxin-induced oxidative stress due to reactive oxygen species (ROS) is associated with 
high cell mortality42. Increasing intracellular ascorbate concentrations, however, decrease ROS levels, thereby 
counteracting cell mortality43.
Ascorbate has been shown to exert antimicrobial effects against distinct bacterial species such as 
Mycobacterium tuberculosis44–47, Staphylococcus aureus, Escherichia coli48, Helicobacter pylori49,50 and Salmonella 
species51 in vitro. Beside direct effects of ascorbate due to its low pH, for instance, reducing cell viability, it is also 
known that ascorbate exerts indirect bactericidal effects in the presence of metal ions or oxygen52. However, 
bacterial biofilm protects the cells against external influences and causes increased tolerance to antibiotic com-
pounds53. Interestingly, ascorbate disrupts bacterial biofilm formation by inhibiting production of extracellular 
polymeric substances in Bacillus subtilis54 and methicillin-resistant S. aureus (MRSA)55 and pyocyanin production 
in Pseudomonas aeruginosa56. Thus, vitamin C (alone or in combination with antibiotics) constitutes a promising 
treatment option to destabilize bacterial biofilms.
Studies in the early 1980s revealed that growth of enteropathogens such as C. jejuni could be inhibited by 
ascorbate at low concentrations52,57,58. The authors have elegantly shown that the antimicrobial activity of ascor-
bate against C. jejuni is not due to lowered pH, but rather depends on the oxidation of ascorbate to dehydroascor-
bate and other products. However, the antimicrobial effects of ascorbate against C. jejuni have not been examined 
further and the exact mechanisms underlying the ascorbate-mediated toxicity against C. jejuni are still not known 
in detail. Moreover, data regarding potential immunomodulatory effects of ascorbate in C. jejuni infection are 
completely missing. This prompted us to perform for the first time a preclinical ascorbate intervention study 
applying our well-established murine clinical model of acute campylobacteriosis. Therefore, microbiota depleted 
IL-10−/− mice were subjected to synthetic ascorbate application via the drinking water, perorally infected with C. 
jejuni and surveyed for gastrointestinal pathogen loads, clinical outcome and intestinal as well as extra-intestinal 
immune responses during campylobacteriosis.
Results
Ascorbate treatment and gastrointestinal pathogen loads in C. jejuni infected secondary abi-
otic IL-10−/− mice. We first assessed antimicrobial effects of synthetic ascorbate against C. jejuni in vitro. 
Studies on minimal inhibitory concentrations (MICs) of 20 different C. jejuni isolates revealed a MIC90 value 
of 2818 mg/L (16 mM) with MICs ranging between 352 and 2818 mg/L (Supplementary Fig. S1). A MIC of 
1409 mg/L (8 mM) was determined for the C. jejuni infection strain 81–176.
Secondary abiotic IL-10−/− mice were subjected to synthetic ascorbate treatment via the drinking water 
starting four days prior C. jejuni infection and lasting until necropsy. The concentration of the applied ascor-
bate solution was 5 g/L and hence, 3.56 times the MIC of the C. jejuni infection strain 81–176. On days 0 and 
1, mice were then perorally challenged with 109 viable C. jejuni bacteria by gavage and surveyed until day 6 
post-infection (p.i.). Bacterial culture analysis of faecal samples over time revealed that ascorbate treatment did 
3Scientific RepoRtS |         (2020) 10:2921  | https://doi.org/10.1038/s41598-020-59890-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
not affect intestinal colonization properties of the applied C. jejuni strain as indicated by comparable median 
loads of approximately 109 colony forming units per gram (CFU/g) derived from ascorbate or placebo (PLC) 
treated mice (n.s.; Supplementary Fig. S2). At day 6 p.i., colonic C. jejuni loads were slightly lower in ascorbate as 
compared to placebo treated mice (i.e., less than one log order of magnitude; p < 0.001; Fig. 1), whereas pathogen 
numbers were comparable in more proximal parts of the gastrointestinal tract including stomach, duodenum and 
ileum (n.s.; Fig. 1). Hence, ascorbate does only marginally affect intestinal C. jejuni colonization in vivo.
Ascorbate treatment ameliorates the clinical outcome of campylobacteriosis in C. jejuni 
infected secondary abiotic IL-10−/− mice. A kinetic survey of the clinical conditions of ascorbate versus 
PLC treated mice revealed that as early as day 5 p.i., the former suffered less distinctly from C. jejuni infection 
as compared to the latter (Supplementary Fig. S3). Upon necropsy (i.e., at day 6 p.i.), placebo treated mice were 
suffering from wasting and severe bloody diarrhea indicative for acute enterocolitis, whereas ascorbate treatment 
resulted in significantly reduced C. jejuni induced symptoms (Fig. 2A; Supplementary Fig. S3), particularly in 
less severe wasting, less pronounced diarrhea, less frequent abundance of blood in faecal samples and in better 
overall clinical appearance (p < 0.05–0.001 vs PLC; Fig. 2). Remarkably, almost 40% of infected mice from the 
ascorbate cohort were clinically uncompromised as indicated by cumulative clinical scores of 0 in 7 out of 18 cases 
(p < 0.001 vs PLC; Fig. 2A; Supplementary Fig. S3). Hence, ascorbate treatment alleviates clinical symptoms of 
campylobacteriosis.
Ascorbate reduces apoptosis in the colon of C. jejuni infected secondary abiotic IL-10−/− mice. 
We next quantitatively assessed pathogen-induced histopathological changes in hematoxylin and eosin (H&E) 
stained colonic paraffin sections applying a standardized histopathological scoring system59. At day 6 p.i., ascor-
bate treated mice displayed a trend towards slightly lower histopathological scores as compared to PLC control 
animal (n.s.; Fig. 3A).
Since apoptosis is regarded as a reliable parameter for the histopathological grading of intestinal inflam-
mation15, we further quantitatively determined apoptotic colonic epithelial cell numbers following in situ 
immunohistochemical staining of colonic paraffin sections with a caspase3 antibody. In fact, C. jejuni infec-
tion was associated with multifold increases in colonic apoptotic epithelial cells at day 6 p.i. (p < 0.001 vs naive, 
whereas this increase was far less pronounced in ascorbate as compared to PLC treated mice (p < 0.001; Fig. 3B; 
Supplementary Fig. S4). Hence, ascorbate treatment decreases C. jejuni induced apoptotic responses in colonic 
epithelial cells.
Less distinct pro-inflammatory immune cell responses in the colon following ascorbate treat-
ment of C. jejuni infected secondary abiotic IL-10−/− mice. We next assessed large intestinal immune 
cell responses following ascorbate treatment of C. jejuni infected mice. C. jejuni infection was associated with 
marked increases of both, innate immune cell populations such as macrophages and monocytes (p < 0.001; 
Fig. 4A; Supplementary Fig. S5a) and adaptive immune cell subsets including T and B lymphocytes (p < 0.01–
0.001; Fig. 4B,C; Supplementary Fig. S5b,c). At day 6 p.i., however, ascorbate treated mice displayed lower num-
bers of macrophages/monocytes as well as of T and B lymphocytes in their colonic mucosa and lamina propria as 
compared to infected PLC control animals (p < 0.01–0.001; Fig. 4; Supplementary Fig. S5). Hence, ascorbate treat-
ment does not only alleviate macroscopic disease and colonic epithelial apoptosis following C. jejuni infection, 
but also dampens immune cell responses in the infected large intestines.
Figure 1. Gastrointestinal pathogen loads following ascorbate treatment of C. jejuni infected secondary 
abiotic IL-10−/− mice. Starting four days before peroral C. jejuni infection on days 0 and 1, secondary abiotic 
IL-10−/− mice were treated with synthetic ascorbate (ASCOR; open circles) or placebo (PLC; filled circles) 
via the drinking water. At day 6 post-infection, C. jejuni were isolated from distinct luminal parts of the 
gastrointestinal tract by culture and pathogenic loads expressed as colony forming units per gram (CFU/g). 
Medians, significance levels (p-values) assessed by the Mann-Whitney U test (for pairwise comparisons of PLC 
vs ASCOR in respective gastrointestinal compartment) and numbers of analyzed animals (in parentheses) are 
indicated. Data were pooled from four independent experiments.
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Reduced pro-inflammatory mediator secretion in the intestinal tract following ascorbate treat-
ment of C. jejuni infected secondary abiotic IL-10−/− mice. We further surveyed pro-inflammatory 
mediator responses in the intestines of ascorbate versus PLC treated C. jejuni infected mice. Six days following C. 
jejuni infection elevated nitric oxide (NO) and tumor necrosis factor (TNF) concentrations could be measured in 
colonic ex vivo biopsies (p < 0.01–0.001 vs naive; Fig. 5A,B), whereas ascorbate treated mice displayed lower medi-
ator levels in their large intestines as compared to PLC control animals (p < 0.05; Fig. 5A,B). Remarkably, elevated 
IL-6 and interferon-γ (IFN-γ) concentrations were determined in colonic ex vivo biopsies at day 6 p.i. of PLC 
(p < 0.01 and p < 0.001 vs naive, respectively), but not ascorbate treated mice (Fig. 5C,D), which also held true 
for IFN-γ levels measured in mesenteric lymph nodes (MLN) at day 6 p.i. (p < 0.001; Fig. 5E). Hence, ascorbate 
treatment dampens pro-inflammatory mediator responses in the large intestines of C. jejuni infected mice.
Figure 2. Macroscopic aspects of ascorbate treated mice following C. jejuni infection. Starting four days 
before peroral C. jejuni infection on days 0 and 1, secondary abiotic IL-10−/− mice were treated with synthetic 
ascorbate (ASCOR; open circles) or placebo (PLC; filled circles) via the drinking water. Applying a standardized 
clinical scoring system (see methods), (A) overall clinical outcome, (B) wasting, (C) abundance of faecal blood 
and (D) stool consistency were quantitatively surveyed at day 6 post-infection. Naive mice (open diamonds) 
served as uninfected controls. Medians, significance levels (p-values) assessed by the Kruskal Wallis test 
followed by Dunns correction and numbers of analyzed animals (in parentheses) are indicated. Data were 
pooled from four independent experiments.
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Figure 3. Histopathological and apoptotic cell responses in colonic epithelia of ascorbate treated mice 
following C. jejuni infection. Starting four days before peroral C. jejuni infection on days 0 and 1, secondary 
abiotic IL-10−/− mice were treated with synthetic ascorbate (ASCOR; open circles) or placebo (PLC; filled 
circles) via the drinking water. (A) Histopathological changes were quantitated in hematoxylin and eosin 
stained colonic paraffin sections applying a standardized scoring system as described in methods. (B) The 
average numbers of apoptotic (positive for caspase3, Casp3+) colonic epithelial cells from six high power fields 
(HPF, 400x magnification) per mouse were assessed microscopically in immunohistochemically stained large 
intestinal paraffin sections at day 6 post-infection. Naive mice (open diamonds) served as uninfected and 
untreated controls. Medians, significance levels (p-values) assessed by the one-way ANOVA test followed by 
Tukey correction and numbers of analyzed animals (in parentheses) are indicated. Data were pooled from four 
independent experiments.
Figure 4. Colonic immune cell responses in ascorbate treated mice following C. jejuni infection. Starting 
four days before peroral C. jejuni infection on days 0 and 1, secondary abiotic IL-10−/− mice were treated with 
synthetic ascorbate (ASCOR; open circles) or placebo (PLC; filled circles) via the drinking water. The average 
numbers of (A) macrophages and monocytes (positive for F4/80), (B) T lymphocytes (positive for CD3), and 
(C) B lymphocytes (positive for B220) in the colonic mucosa and lamina propria from six high power fields 
(HPF, 400x magnification) per mouse were assessed microscopically in immunohistochemically stained large 
intestinal paraffin sections at day 6 post-infection. Naive mice (open diamonds) served as uninfected and 
untreated controls. Medians, significance levels (p-values) assessed by the one-way ANOVA test followed by 
Tukey correction and numbers of analyzed animals (in parentheses) are indicated. Data were pooled from four 
independent experiments.
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Amelioration of inflammatory responses in extra-intestinal compartments following ascorbate 
treatment of C. jejuni infected secondary abiotic IL-10−/− mice. We further addressed whether 
the ascorbate associated disease-alleviating effects could also be observed in extra-intestinal compartments. 
We therefore quantitatively assessed apoptotic cell responses in kidneys, lungs and liver applying in situ immu-
nohistochemistry. Six days following C. jejuni infection, increased numbers of caspase3+ cells could be deter-
mined in the kidneys and lungs of PLC (p < 0.01–0.001 vs naive), but not of ascorbate treated mice (Fig. 6A,B; 
Supplementary Fig. S6a,b). C. jejuni infected mice from either cohort displayed elevated hepatic apoptotic cell 
numbers (p < 0.01–0.001 vs naive), but with a trend towards lower numbers following ascorbate as compared to 
PLC application (n.s.; Fig. 6C; Supplementary Fig. S6c). Furthermore, PLC (p < 0.001 vs naive), but not ascor-
bate treated mice exhibited increased numbers of CD3+ T lymphocytes in their livers (Fig. 7A; Supplementary 
Fig. S6d), that was accompanied by elevated C. jejuni induced hepatic TNF secretion in the former, but not the 
latter cohort (p < 0.05 vs PLC; Fig. 7B).
We finally surveyed whether viable pathogens had translocated from the intestinal tract to extra-intestinal 
including systemic tissue sites following ascorbate treatment. C. jejuni translocation frequencies to MLN, spleen 
and liver were rather comparable following either treatment regimen at day 6 p.i. (Supplementary Fig. S7), whereas 
viable bacteria were isolated from the kidneys and lungs of PLC treated mice in single cases only, but in none of 
the animals from the ascorbate cohort (Supplementary Fig. S7). Of note, all blood samples taken at day 6 p.i. were 
C. jejuni-culture negative. Hence, the disease-alleviating effects of ascorbate treatment in C. jejuni infected mice 
were not restricted to the intestinal tract but could also be observed in extra-intestinal compartments.
Discussion
In this preclinical intervention study, we addressed for the first time potential anti-pathogenic and immunomodu-
latory properties of vitamin C during experimental acute campylobacteriosis in a clinical murine infection model. 
Following adding ascorbate to the drinking water starting four days prior C. jejuni infection of microbiota depleted 
IL-10−/− mice the excessively high gastrointestinal pathogen loads (of up to 109 viable bacterial cells per g faeces) 
Figure 5. Intestinal inflammatory mediator responses in ascorbate treated mice following C. jejuni infection. 
Starting four days before peroral C. jejuni infection on days 0 and 1, secondary abiotic IL-10−/− mice were 
treated with synthetic ascorbate (ASCOR; open circles) or placebo (PLC; filled circles) via the drinking water. At 
day 6 post-infection. pro-inflammatory mediators including (A) nitric oxide, (B) TNF, (C) IL-6 and (D) IFN-γ 
were measured in supernatants of ex vivo biopsies derived from the colon as well as (E) IFN-γ concentrations 
assessed in mesenteric lymph nodes (MLN). Naive mice served as negative controls (open diamonds). Medians, 
significance levels (p-values) assessed by the Kruskall Wallis test followed by Dunns correction and numbers of 
analyzed animals (in parentheses) are indicated. Data were pooled from four independent experiments.
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Figure 6. Extra-intestinal apoptosis in ascorbate treated mice following C. jejuni infection. Starting four days 
before peroral C. jejuni infection on days 0 and 1, secondary abiotic IL-10−/− mice were treated with synthetic 
ascorbate (ASCOR; open circles) or placebo (PLC; filled circles) via the drinking water. At day 6 post-infection, 
the average numbers of apoptotic cells (positive for caspase-3, Casp3+) from six high power fields (HPF, 400x 
magnification) per mouse were assessed microscopically in immunohistochemically stained paraffin sections 
derived from (A) liver, (B) kidneys and (C) lungs. Naive mice served as uninfected and untreated controls 
(open diamonds). Medians, significance levels (p-values) assessed by the Kruskal Wallis test followed by Dunns 
correction and numbers of analyzed animals (in parentheses) are indicated. Data were pooled from four 
independent experiments.
Figure 7. Hepatic inflammatory immune responses in ascorbate treated mice following C. jejuni infection. 
Starting four days before peroral C. jejuni infection on days 0 and 1, secondary abiotic IL-10−/− mice were 
treated with synthetic ascorbate (ASCOR; open circles) or placebo (PLC; filled circles) via the drinking water. 
At day 6 post-infection, the average numbers of (A) T lymphocytes (positive for CD3) from six high power 
fields (HPF, 400x magnification) per mouse were assessed microscopically in immunohistochemically stained 
paraffin sections derived from liver ex vivo biopsies. Furthermore, (B) TNF concentrations were determined 
in supernatants of hepatic ex vivo biopsies taken at day 6 p.i. Naive mice served as negative controls (open 
circles). Numbers of mice (in parentheses), medians (black bars) and significance levels (p-values) determined 
by the one-way ANOVA test followed by Tukey correction are indicated. Data shown were pooled from three 
independent experiments.
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within the stably infected animals could only marginally be lowered by less than one order of magnitude until day 
6 p.i. This result was not surprising given that the ascorbate concentration within the drinking water exceeded 
approximately 3.5 times the MIC against the applied C. jejuni strain but is reduced by mixing with the secretory 
body fluids in the intestinal tract of the animals. The potent antibacterial properties of ascorbate directed against 
food-borne pathogens such as C. jejuni52,57,58 and Salmonella species51,60,61 have been further supported by several 
previous in vitro studies. Initially, it was hypothesized that the antimicrobial effects of vitamin C were particularly 
due to its pH lowering properties62. But this is not the case for the antimicrobial activity of ascorbate against C. 
jejuni, which depends on oxidation of ascorbate to dehydroascorbic acid and other products, as confirmed in 
independent studies in vitro52,58.
Despite the high gastrointestinal pathogen burdens, ascorbate treatment resulted in much better overall 
clinical conditions of C. jejuni infected mice including less severe diarrhea and less frequent abundance of fae-
cal blood. It is noteworthy that almost 40% of mice from the ascorbate cohort were clinically uncompromised 
whereas mice from the placebo group suffered from full-blown campylobacteriosis as indicated by wasting and 
bloody diarrhea. The better macroscopic outcome upon ascorbate pretreatment of C. jejuni infected mice was 
accompanied by less apoptotic colonic epithelial cell responses. In support, Helicobacter pylori-induced apop-
tosis in human gastric epithelial cells was shown to be dampened after ascorbate treatment63, whereas another 
study revealed that intracellular accumulation of ascorbate could suppress apoptotic pathways in human mono-
cytes in vitro64. Moreover, co-incubation with ascorbate promoted proliferative properties of human peripheral 
T lymphocytes65,66.
In addition to exerting antimicrobial effects, vitamin C has been shown to exhibit potent immunomodu-
latory, particularly anti-inflammatory properties both, in vitro and in vivo67–69. In our present study, ascorbate 
treatment resulted in less pronounced C. jejuni-induced pro-inflammatory innate as well as adaptive immune 
responses as indicated by lower numbers of macrophages and monocytes as well as of T and B lymphocytes, 
respectively, within the inflamed colonic mucosa and lamina propria that were accompanied by less intestinal 
secretion of pro-inflammatory mediators including nitric oxide, TNF, and IFN-γ and IL-6 at day 6 p.i. In support, 
ascorbate co-incubation resulted in down-regulated TNF levels in human whole blood70 and in splenic mouse 
T cell cultures71, whereas decreased nitric oxide, TNF, IFN-γ, and IL-6 concentrations could be determined in 
Staphylococcus aureus infected murine peritoneal macrophages in vitro40. Furthermore, ascorbate application 
to healthy subjects enhanced natural killer cell activities, lymphocyte proliferation and chemotaxis72,73, further 
underlining the potent immunomodulatory, anti-inflammatory effects of vitamin C69.
Notably, the anti-inflammatory effects of ascorbate treatment in C. jejuni infected mice were not restricted to 
the intestinal tract, but could also be observed in extra-intestinal organs as indicated by less distinct apoptosis in 
liver, kidneys and lungs and lower T cell numbers and lower TNF concentrations in livers of ascorbate versus pla-
cebo treated mice. Interestingly, translocation frequencies of viable C. jejuni from the intestinal tract to the liver 
were rather comparable following either treatment regimen, whereas no viable bacteria at all could be isolated 
from the kidneys and lungs following ascorbate pretreatment and in single cases only in placebo control mice at 
day 6 p.i.
The here presented immunomodulatory properties of an externally applied vitamin during acute C. jejuni 
induced enterocolitis are further supported by our very recent study surveying the health beneficial (i.e, 
anti-inflammatory) effects of vitamin D in the same clinical murine campylobacteriosis model. Following 
pre-treatment with synthetic 25-OH cholecalciferol, secondary abiotic IL-10−/− mice (i.) harbored comparably 
high C. jejuni loads in their gastrointestinal tract alike placebo controls upon peroral infection, but (ii.) suf-
fered less frequently from diarrhea in the midst of infection, displayed (iii.) less pathogen-induced apoptotic, 
but (iv.) more pronounced counter-regulatory regenerative colonic cell responses that were accompanied by (v.) 
less distinct recruitment of both, innate und adaptive immune cells to the infected intestines, and by (vi.) less 
secretion of pro-inflammatory mediators in the intestinal tract (i.e, colon, ileum und MLN) as well as in the 
liver. Furthermore, as opposed to placebo controls (vii.) vitamin D treated mice displayed an uncompromised 
colonic epithelial barrier function which was accompanied by (viii.) less distinct bacterial translocation from the 
inflamed gut to extra-intestinal compartments in the latter as compared to the former74.
The pharmacokinetic properties of ascorbate in the vertebrate host are well studied75–79. Murine investigations 
on absorption, tissue distribution and retention of ascorbate76–78 revealed that maximum ascorbate concentra-
tions could be measured in liver and kidneys (alike in the urine of humans75) approximately three hours following 
peroral single dose application76. Whereas in the lungs, adrenal glands, skin, white fat and pancreas peak levels 
were detectable as early as 6 hours, in the spleen increasing ascorbate concentrations could still be assessed until 
24 hours following application76. The risk of adverse effects and intoxication upon high-dose ingestion may be 
considered negligible in subjects with intact renal function, given that vitamin C is water-soluble and concen-
trations exceeding the daily demands will be excreted via the kidneys80.Together, ascorbate application can be 
considered as safe and has been pharmaceutically approved for the treatment of gastrointestinal morbidities in 
humans33,60,81. Interestingly, several inflammatory morbidities within the gastrointestinal tract have been shown 
to be associated with reduced ascorbate plasma concentrations82,83.
In conclusion, our pre-clinical intervention study provides strong evidence for the first time that ascorbate 
constitutes a promising compound exerting potent anti-inflammatory and hence, disease-alleviating effects in 
non-self-limiting acute campylobacteriosis. Furthermore, food supplementation with ascorbate might be a use-
ful tool to enhance host defense mechanisms in livestock animals directed against enteropathogens including 
C. jejuni thereby lowering pathogenic loads or even preventing from pathogen acquisition. Further studies are 
needed, however, to unravel the underlying mechanism in more detail.
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Material and Methods
ethical statement. In vivo experiments were carried out according to the European Guidelines for animal 
welfare (2010/63/EU) following agreement by the commission for animal experiments headed by the “Landesamt 
für Gesundheit und Soziales” (LaGeSo, Berlin, registration number G0172/16 and G0247/16). Animal welfare 
was monitored twice a day.
Determination of minimal inhibitory concentrations of ascorbate. To determine the antimicrobial 
effect of synthetic ascorbate, 20 C. jejuni isolates including the reference strain 81–176 (used for infection of mice, 
see below) and the DSM 4688 strain (for quality control) were tested in three independent experiments for their 
minimal inhibitory concentration (MIC) by the broth microdilution and macrodilution method. Settings of inoc-
ulum density, growth medium and conditions as well as incubation time were applied following the recommen-
dations of the Clinical and Laboratory Standards Institute (CLSI) given in the document VET01-Ed584. Twofold 
serial dilutions ranging from 0.03–32.0 mmol/L (6–5636 µg/mL) for ascorbate were tested. Stock solutions were 
prepared in Mueller-Hinton broth (Oxoid, Germany) and adjusted to pH 7.3.
Generation of secondary abiotic/gnotobiotic mice. In the identical unit of the Forschungseinrichtungen 
für Experimentelle Medizin (FEM, Charité - University Medicine Berlin), IL10−/− mice (C57BL/6j background) were 
bred, raised and housed under specific pathogen free (SPF) conditions. Mice were kept under standard conditions 
(22–24 °C room temperature, 55 ± 15% humidity, 12 h light/12 h dark cycle) in cages including filter tops within an 
experimental semi-barrier (accessible only with lab coat, overshoes, caps and sterile gloves) and had free access to auto-
claved standard chow (food pellets: ssniff R/M-H, V1534-300, Sniff, Soest, Germany) as well as to autoclaved drinking 
water (ad libitum).
The depletion of the murine commensal intestinal microbiota in order to abrogate the physiological coloni-
zation resistance and hence, to assure stable intestinal C. jejuni colonization was achieved by application of five 
different antibiotics to the mice15,85. Briefly, 3-week old mice were treated with an antibiotic cocktail contain-
ing vancomycin (500 mg/L; Cell Pharm, Germany), ciprofloxacin (200 mg/L; Bayer Vital, Germany), imipenem 
(250 mg/L; MSD, Germany), metronidazole (1 g/L; Fresenius, Germany), and ampicillin plus sulbactam (1 g/L; 
Ratiopharm, Germany) within autoclaved drinking water (ad libitum) over a period time of 8 weeks. Three days 
prior infection the antibiotic treatment was withdrawn to assure antibiotic washout.
treatment with synthetic ascorbate. Starting four days before C. jejuni infection and lasting until the 
end of the experiment, three-month old, sex-matched secondary abiotic IL-10−/− mice (maximum of three ani-
mals per cage) were treated with ascorbate (Sigma Aldrich, München, Germany) that had been sterile-filtered and 
added to the autoclaved tap water (ad libitum) and changed every other day. For ascorbate treatment, a daily dos-
age of 1 g per kg body weight was calculated86. Considering a body weight of approximately 25 g per mouse and 
a daily drinking volume of approximately 5 mL, the final concentration of the ascorbate solution was 5 g/L (pH 
7.0). Mice from the placebo (PLC) cohort received autoclaved tap water only. Of note, the daily inter-individual 
drinking volumes between cages within and between respective cohorts were comparable. In four individual 
experiments, n = 5/5/4/4 ascorbate treated mice and n = 6/6/6/6 PLC controls were analyzed.
C. jejuni infection. As previously described, mice were challenged with 109 CFU of the C. jejuni strain 
81–176 (that had initially been isolated from a diseased patient suffering from bloody diarrhea) in a volume of 
0.3 mL phosphate buffered saline (PBS; Gibco, life technologies, UK) on two successive days (days 0 and 1) by oral 
gavage15. In order to avoid contaminations, mice were kept and handled under strict aseptic conditions.
evaluation of clinical conditions. The clinical conditions of mice were evaluated daily (starting four days 
before and lasting until day 6 after C. jejuni infection) and quantitated via standardized cumulative clinical scores 
(maximum 12 points), addressing the abundance of blood in faeces (0: no blood; 2: microscopic detection of 
blood by the Guajac method using Haemoccult, Beckman Coulter/PCD, Germany; 4: macroscopic blood visible), 
stool consistency (0: formed faeces; 2: pasty faeces; 4: liquid faeces), and the clinical aspect (0: normal; 2: ruffled 
fur, less locomotion; 4: isolation, severely compromised locomotion, pre-final aspect) as described earlier27.
Sampling methods. Six days after the infection, mice were sacrificed by inhalation of isoflurane (Abbott, 
Germany). Luminal gastrointestinal samples (i.e., from colon, ileum, duodenum, and stomach) and ex vivo 
biopsies from intestinal (colon, ileum, MLN) and extra-intestinal (liver, kidneys and lungs) compartments were 
taken under aseptic conditions. To generate individual serum probes, cardiac blood was collected (approximately 
1.0 mL). Intestinal samples for microbiological, immunological and immunohistopathological assays were taken 
in parallel from each mouse.
Histopathology. For histopathological analyses, sections (thickness 5 µm) of formalin-fixed (5%) and 
paraffin-embedded colonic ex vivo biopsies were used, stained with hematoxylin and eosin (H&E), and examined 
by light microscopy (100x magnification). The histopathological changes in the large intestines were quanti-
tatively evaluated following an established histopathological scoring system ranging from 0 to 4 as described 
earlier59. Score 1: intact epithelium with minimal inflammatory cell infiltrates in the mucosa. Score 2: mild hyper-
plasia and mild goblet cell loss with mild inflammatory cell infiltrates in the mucosa and submucosa. Score 3: 
moderate goblet cell loss with moderate inflammatory cell infiltrates in the mucosa. Score 4: marked goblet cell 
loss, multiple crypt abscesses and crypt loss with marked inflammatory cell infiltration into in the mucosa and 
submucosa.
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immunohistochemical assays. In situ immunohistochemical analyses were conducted as previously 
reported87,88. Briefly, paraffin sections (5 μm) derived from ex vivo biopsies of interest (i.e., colon, liver, kidneys, 
lungs) were stained with primary antibodies directed against cleaved caspase 3 (Asp175, Cell Signaling, Beverly, 
MA, USA, 1:200) to detect apoptotic epithelial cells; with F4/80 (# 14–4801, clone BM8, eBioscience, San Diego, 
CA, USA, 1:50) to detect macrophages/monocytes; with CD3 (#N1580, Dako, 1:10) to detect T lymphocytes; and 
furthermore, with B220 (No. 14-0452-81, eBioscience; 1:200) to detect B lymphocytes. The sections were incu-
bated with the primary antibody for 30 min followed by another 30 min of incubation with the respective second-
ary antibody (for anti-caspase-3 and anti-CD3 staining: biotinylated donkey anti-rabbit antibody; for anti-F4/80 
and anti-B220: biotinylated rabbit anti-rat antibody; all from Dianova, Hamburg, Germany). As detection system, 
the Streptavidin-Alkaline Phosphatase Kit (Dako) using Fast Red as chromogen was applied. To generate negative 
controls, the primary antibodies had been excluded. The examination of positively stained cells was undertaken 
by light microscopy (magnification 100x and 400x). The average number of respective positively stained cells 
for each mouse was calculated within at least six high power fields (HPF, 0.287 mm2, 400x magnification) by a 
blinded independent investigator. An Axiolmager Z1 microscope was used for the generation of images, which 
were subsequently processed with the Axiovision software (Carl Zeiss MicroImaging, Jena, Germany).
the colonization and translocation of C. jejuni. The C. jejuni loads were quantitatively surveyed in 
faeces samples taken every days after infection, and further, upon necropsy in gastrointestinal luminal samples 
(taken from stomach, duodenum, ileum and colon) and in homogenized ex vivo biopsies derived from MLN, 
spleen, liver, kidneys and lungs as well as in cardiac blood by culture as stated earlier15,89. The detection limit of 
viable pathogens was ≈100 CFU per g. For the determination of cumulative translocation rates of viable C. jejuni 
into respective extra-intestinal compartments, the ratio of the sum of culture-positive mice and the total numbers 
of analyzed animals (in %) out of four experiments were calculated.
Measurements of intestinal and extra-intestinal pro-inflammatory mediators. Longitudinally 
sliced and in PBS washed colonic ex vivo biopsies (strips of approximately 1 cm2) as well as ex vivo biopsies derived 
from liver (approximately 1 cm3) and MLN (3–4 lymph nodes) were cultured for 18 h at 37 °C in 24-flat-bottom 
well culture plates (Nunc, Germany) containing 500 μL serum-free RPMI 1640 medium (Gibco, life technolo-
gies, UK) that was supplemented with penicillin (100 U/mL) and streptomycin (100 µg/mL; PAA Laboratories, 
Germany). Using the Mouse Inflammation Cytometric Bead Assay (CBA; BD Biosciences, Germany) the cul-
ture supernatants and serum samples were analyzed for TNF, IFN-γ and IL-6 on a BD FACS Canto II flow 
cytometer (BD Biosciences). The nitric oxide concentrations were determined by the Griess reaction85,90. The 
pro-inflammatory mediator levels were normalized to the protein concentrations measured in the supernatant of 
the respective organ homogenate88.
Data analysis. Data from four independently performed experiments were pooled and analyzed. The 
Mann-Whitney test (GraphPad Prism v7, USA) was used for determination of medians and levels of significance 
for pairwise comparisons of not normally distributed data, whereas for multiple comparisons, the one-sided 
ANOVA with Tukey post-correction or the Kruskal-Wallis test with Dunn’s post-correction were used. Two-sided 
probability (p) values ≤ 0.05 were considered significant.
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